Based on the Medicenna Therapeutics Corp stock forecast from 2 analysts, the average analyst target price for Medicenna Therapeutics Corp is CAD 3.50 over the next 12 months. Medicenna Therapeutics Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Medicenna Therapeutics Corp is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Medicenna Therapeutics Corp’s stock price was CAD 1.95. Medicenna Therapeutics Corp’s stock price has changed by +16.77% over the past week, +30.00% over the past month and +116.67% over the last year.
No recent analyst target price found for Medicenna Therapeutics Corp
No recent average analyst rating found for Medicenna Therapeutics Corp
Company Overview Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada. Read Less
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblast...Read More
Frequently Asked Questions About Medicenna Therapeutics Corp (MDNA:CA) Stock
Based on ratings from 2 analysts Medicenna Therapeutics Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on MDNA:CA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for MDNA:CA is CAD 3.50 over the next 12 months. The maximum analyst target price is CAD 6 while the minimum anlayst target price is CAD 1.
MDNA:CA stock's Price/Earning ratio is 5.40.
Our analysis grades MDNA:CA stock's Price / Earning ratio at A+. This means that MDNA:CA stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the TSX exchange.
Based on this MDNA:CA may be undervalued for its sector.
The last closing price of MDNA:CA's stock was CAD 1.95.
The most recent market capitalization for MDNA:CA is CAD 0.11B.
Based on targets from 2 analysts, the average taret price for MDNA:CA is projected at CAD 3.50 over the next 12 months.
This means that MDNA:CA's stock price may go up by +79.49% over the next 12 months.
We can't find any ETFs which contains Medicenna Therapeutics Corp's stock.
As per our most recent records Medicenna Therapeutics Corp has 16 Employees.
Medicenna Therapeutics Corp's registered address is 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2.
You can get more information about it from Medicenna Therapeutics Corp's website at https://www.medicenna.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MDNA:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
